株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

有機リンおよびカーバメート中毒 : パイプライン製品の分析

Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 357980
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.09円で換算しております。
Back to Top
有機リンおよびカーバメート中毒 : パイプライン製品の分析 Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 36 Pages
概要

有機リンおよびカーバメートは、一般的な殺虫剤であり、コリンエステラーゼ活性を阻害し、急性のムスカリン様作用(唾液分泌、流涙、排尿、下痢、嘔吐、気管支漏、気管支痙攣、徐脈、縮瞳)および、筋攣縮や筋力低下などのニコチン様作用を引き起こします。ほとんどの患者には徐脈作用が見られ、中毒がひどいと 低血圧症が見られる場合もあります。中枢神経系毒性が一般的であり、発作や興奮を伴うこともあり、倦怠感に襲われたり、昏睡状態になることもよくあります。膵炎になる可能性もあり、有機リン酸エステルによって心臓ブロックやQT間隔延長などのような不整脈が引き起こされることもあります。

当レポートでは、有機リンおよびカーバメート中毒治療薬の開発状況について調査分析しており、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などの情報を提供しています。

イントロダクション

  • 調査範囲

有機リンおよびカーバメート中毒の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

有機リンおよびカーバメート中毒の治療薬開発に従事している企業

  • Countervail Corporation
  • Hager Biosciences, LLC

薬剤プロファイル

有機リンおよびカーバメート中毒:開発が中止された製品

有機リンおよびカーバメート中毒:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

目次
Product Code: GMDHC10398IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Organophosphate and Carbamate Poisoning - Overview
  • Organophosphate and Carbamate Poisoning - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Organophosphate and Carbamate Poisoning - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
  • Countervail Corp
  • Hager Biosciences LLC
  • Organophosphate and Carbamate Poisoning - Drug Profiles
  • AM-132 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galantamine hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PlantVax-1502-H-N - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Butyrylcholinesterase for Organophosphate and Carbamate Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RS-194B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Organophosphate Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Organophosphate and Carbamate Poisoning - Discontinued Products
  • Organophosphate and Carbamate Poisoning - Product Development Milestones
  • Featured News & Press Releases
  • Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent for Organophosphorus Poisoning awarded
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 4: Products under Development by Companies, H1 2018
  • Table 5: Products under Development by Universities/Institutes, H1 2018
  • Table 6: Number of Products by Stage and Target, H1 2018
  • Table 7: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 8: Number of Products by Stage and Route of Administration, H1 2018
  • Table 9: Number of Products by Stage and Molecule Type, H1 2018
  • Table 10: Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, H1 2018
  • Table 11: Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences LLC, H1 2018
  • Table 12: Organophosphate and Carbamate Poisoning - Discontinued Products, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Targets, H1 2018
  • Figure 5: Number of Products by Stage and Targets, H1 2018
  • Figure 6: Number of Products by Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Routes of Administration, H1 2018
  • Figure 10: Number of Products by Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Molecule Types, H1 2018
Back to Top